Viracept Powder (Oral)
Nelfinavir
50mg/g
F. Hoffmann-La Roche Ltd.
| Pack size | 144g Plastic Bottle |
|---|---|
| Dispensing mode | POM |
| Source | SWITZERLAND |
| Agent | IBN KHALDOON DRUG STORE |
| Retail Price | 317.50 AED |
Available as:
Indications
Viracept Powder (Oral) is used for:
HIV infection
Adult Dose
Oral
HIV infection
Adult: Combined with other antiretrovirals: 1.25 g bid or 0.75 g tid.
Hepatic Impairment
Mild impairment (Child-Pugh class A): Dose adjustment not necessary
Severe impairment (Child-Pugh Class B or C): Not recommended
Child Dose
Oral
HIV infection
Child: Combined with other antiretrovirals:
2-13 yr: 45-55 mg/kg bid or 25-35 mg/kg tid. Max: 0.75 g tid.
Max Dosage: Child: 0.75 g tid.
Renal Dose
Renal Impairment
Dose adjustment not necessary
Administration
Should be taken with food.
Contra Indications
Hypersensitivity; lactation.
Precautions
Pregnancy. Hepatic and renal impairment; haemophilia A or B; diabetes. Monitor for signs of lipodystrophy.
Lactation: HIV+ women are advised not to breastfeed
Pregnancy-Lactation
Pregnancy Category: B
Lactation: HIV+ women are advised not to breastfeed
Interactions
Reduced levels/effects with antacids, phenobarbital, carbamazepine, aminoglutethimide, phenytoin, rifampicin, nafcillin, nevirapine, omeprazole, nevirapine. Increased serum levels/effects with azole antifungal agents, cimetidine, efavirenz. Increased serum levels/effects of azithromycin, calcium channel blockers, clarithromycin, corticosteroids (e.g. fluticasone), mirtazapine, nateglinide, nefazodone, ciclosporin, sirolimus, tacrolimus, venlafaxine, eplerinone, fentanyl, atorvastatin, phosphodiesterase-5 (PDE-5) inhibitors, rifabutin, trazodone, TCAs. Reduced serum levels/effects of hormonal contraceptives, methadone, theophylline derivatives.
Potentially Fatal: Increased serum levels/toxicity of amiodarone, cisapride, pimozide, midazolam, triazolam, ergot alkaloids, lovastatin, simvastatin, quinidine.
Adverse Effects
Side effects of Nelfinavir :
>10%
Diarrhea (14-20%)
1-10%
Nausea (3-7%), Flatulence (1-5%), Abdominal pain (1%), Anemia (1%), Allergic reaction (1%), Impaired concentration (1%), Lipodystrophy (1%), Metabolic acidosis (1%), Rash (1-3%), Leukopenia (1%), Thrombocytopenia (1%), Weakness (1%)
<1%
QTc prolongation, Torsades de pointes, Diabetes mellitus, new onset and exacerbation, Hyperglycemia
Mechanism of Action
Nelfinavir is a selective, competitive, reversible HIV protease inhibitor. It inhibits HIV-1 protease preventing the cleavage of the gag-pol polyprotein resulting in the production of noninfectious virus.
Note
Viracept 50mg/g Powder (Oral) manufactured by F. Hoffmann-La Roche Ltd.. Its generic name is Nelfinavir. Viracept is availble in United Arab Emirates.
Farmaco UAE drug index information on Viracept Powder (Oral) is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.